1. Home
  2. KLAR vs APGE Comparison

KLAR vs APGE Comparison

Compare KLAR & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KLAR

Klarna Group plc Ordinary Shares

N/A

Current Price

$12.97

Market Cap

4.6B

Sector

Finance

ML Signal

N/A

Logo Apogee Therapeutics Inc.

APGE

Apogee Therapeutics Inc.

HOLD

Current Price

$86.57

Market Cap

4.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLAR
APGE
Founded
2005
2022
Country
United Kingdom
United States
Employees
2831
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6B
4.7B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
KLAR
APGE
Price
$12.97
$86.57
Analyst Decision
Buy
Strong Buy
Analyst Count
15
13
Target Price
$39.57
$109.67
AVG Volume (30 Days)
5.7M
1.1M
Earning Date
05-18-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$28.75
N/A
Revenue Next Year
$19.94
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.06
$31.21
52 Week High
$47.48
$87.00

Technical Indicators

Market Signals
Indicator
KLAR
APGE
Relative Strength Index (RSI) 40.93 66.36
Support Level $12.28 $73.06
Resistance Level $16.78 N/A
Average True Range (ATR) 0.78 4.44
MACD 0.25 0.76
Stochastic Oscillator 44.60 89.83

Price Performance

Historical Comparison
KLAR
APGE

About KLAR Klarna Group plc Ordinary Shares

Klarna Group PLC is a technology-driven payments company, with operations spanning multiple countries. It connects consumers and merchants with comprehensive payment solutions and tailored advertising solutions, both online and offline. Its payment solutions provide consumers with more control and flexibility over their payments. It is a digital bank and flexible payments provider building the next-generation AI-powered commerce network.

About APGE Apogee Therapeutics Inc.

Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Share on Social Networks: